Asthma Clinical Trial
Official title:
Prediction of Patient Deterioration Using Machine Learning
Verified date | September 2021 |
Source | Brigham and Women's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict patient deterioration throughout a patient's admission. This algorithm was then validated in a validation cohort.
Status | Active, not recruiting |
Enrollment | 500 |
Est. completion date | December 1, 2021 |
Est. primary completion date | December 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Cared for in the Brigham and Women's Home Hospital study Exclusion Criteria: Incomplete continuous monitoring data |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Faulkner Hospital | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital | Biofourmis Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Alarm burden | The number of alarms fired per patient per hour | From admission to discharge, measured in hours, on average 5 days | |
Secondary | Sensitivity for recognition of a safety composite | The sensitivity (true positives divided by condition positives) for detection of a safety composite (overnight visit, extra unplanned visit, transfer back to the hospital, death during admission, delirium, loss of consciousness, or other major event). | From admission to discharge, on average 5 days | |
Secondary | Specificity for recognition of a safety composite | The specificity (true negatives divided by condition negatives) for detection of a safety composite (overnight visit, extra unplanned visit, transfer back to the hospital, death during admission, delirium, loss of consciousness, or other major event). | From admission to discharge, on average 5 days | |
Secondary | Positive predictive value for recognition of a safety composite | The positive predictive value (true positives divided by the sum of true positives plus false positives) for detection of a safety composite (overnight visit, extra unplanned visit, transfer back to the hospital, death during admission, delirium, loss of consciousness, or other major event). | From admission to discharge, on average 5 days | |
Secondary | Negative predictive value for recognition of a safety composite | The negative predictive value (true negatives divided by the sum of true negatives plus false negatives) for detection of a safety composite (overnight visit, extra unplanned visit, transfer back to the hospital, death during admission, delirium, loss of consciousness, or other major event). | From admission to discharge, on average 5 days | |
Secondary | Rate of alarms with clinical utility | We will use general estimating equations (GEE) with three outcomes per patient (the number of clinically important alarms for BioVitals, NEWS2, and traditional vital signs); the GEE will account for the clustering between the three outcomes on a patient. The GEE will use a negative binomial marginal model with a log-link for the number of alarms with clinical utility and an offset for log length-of stay (in hours); with this model, we model the rate per hour of number of alarms with clinical utility with BI, NEWS2, and traditional vital signs. The main covariate in the negative binomial model will be a three-level covariate for method: BI vs NEWS2 vs traditional vital signs, and the exponential of the effect of this covariate will be a pair-wise rate ratio for BI vs NEWS2 vs traditional vital signs. | From admission to discharge, on average 5 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|